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ception for the latter were not available.
Clinical examination was unremarkable apart from a palpable right
breast lump, shown to be consistent with lactational change on mam-
mogram and ultrasound investigation. Pelvic ultrasound did not reveal
an obvious ectopic pregnancy or underlyingmass. She underwent a lap-
aroscopy and dilation and curettage to exclude an ectopic pregnancy or
malignancy. The histology fromendometrial curettingswas normal. The
patient elected to have bilateral salpingectomies performed at the same
time as her family was complete.
The initialworking diagnosiswas of an occult ectopic pregnancy andIntroduction
Familial hCG syndrome is a rare condition and was ﬁrst described in
2009.(Cole, 2012) Affected family members produce a mutated form of
hCG with multiple alterations in the C-Terminal Peptide region of the
hCG molecule, resulting in persistently elevated Human Chorionic
Gonadotropin (hCG) levels. The site of origin of the mutated hCG is
still unknown but does not appear to arise from trophoblastic tissue or
the pituitary. The syndrome does not have clinical sequelae; in particu-
lar, it does not appear to affect fertility.
We present a case of a 34-year-old woman diagnosed with familial
hCG syndrome which we believe is the ﬁrst to be reported in New
Zealand.Case report
A 34-year-old Polynesian woman, presented to the Gynaecology
services with intermittent vaginal bleeding and a raised total serum
hCG of 96 IU/L (Abbott Architect, Abbott Laboratories. Reference
Range b5 IU/L) which was conﬁrmed on weekly serial hCG levels over
the precedingmonth. She did not have a signiﬁcant pastmedical history
or family history and was not on regular medications. Her reproductive
history included four live births (themost recent was a term pregnancy
six months prior to presentation), a spontaneous miscarriage and ackland City Hospital, Auckland,
c. This is an open access article underthe patient received two doses of intramuscularmethotrexate. The total
hCG levels did not change and shewas referred to the Gynaecologic On-
cologyMulti-disciplinaryMeeting (MDM). The outcomeof theMDMre-
view was a referral to the Medical Oncology services with a presumed
diagnosis of gestational trophoblastic neoplasia (GTN) — persistently
raised total hCG for more than six months following an antecedent
term pregnancy. Repeat imaging with a transvaginal ultrasound, CT
body and MRI head did not reveal any abnormal ﬁndings apart from
an incidental ﬁnding of an enlarged right axillary node which was
shown to be a reactive node on biopsy.
Treatment options for gestational trophoblastic neoplasia were
discussed, including systemic chemotherapy with methotrexate or
total hysterectomy. The rarer diagnosis of placental site trophoblastic
tumour (PSTT)was considered, for which primary treatment is a radical
hysterectomy. The patient was reluctant to undergo chemotherapy and
because of the possibility of occult PSTT, she was referred for a total
hysterectomy.
During the diagnostic work-up, serum and urine samples were
sent to the USA hCG Reference Service based in the United States for
further analysis. This revealed a raised total hCG in both serum
and urine (206 IU/L and of 215 IU/L respectively, Siemens Immulite,
Siemens Healthcare Global. Reference Range b5 IU/L), excluding a
false positive hCG test. Additionally, the follicle stimulating hormone
level of 4.6 IU/L (Siemens Immulite, Siemens Healthcare Global) was
within normal range for a womanwith normal menstrual cycle and ex-
cluded a pituitary source for hCG. She had a low hyperglycosylated hCG
level of b5.5 IU/L (microtiter plate assay, USA hCG Reference Service.
Reference Range b5.5 IU/L) or b 2.7% of total hCGwhich excluded active
gestational trophoblastic disease (GTD) although quiescent GTD
remained a differential (Cole et al., 2006).
In the absence of radiological and histological evidence for occult
malignancy and given the initial laboratory ﬁndings, a rarer differentialthe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Table 1
Plasma total hCG results for index case and her four children.
Sex Age Abbott Architect
Total hCG IU/L
Roche Cobas
Total hCG IU/L
Patient F 34 years 82 120
Child 1 M 12 years 119 180
Child 2 F 6 years 101 140
Child 3 M 4 years 115 160
Child 4 F 8 mths 133 190
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assay detects hCG missing the ß-subunit C-terminal peptide seg-
ment (CTP), nicked hCG and hyperglycosylated hCG equally. Her total
hCG measured with the Siemens Immulite assay was 206 IU/L. The
Siemens Dimension assay which utilises carbohydrate-sensitive
detection antibodies directed towards the ß-subunit CTP alone gave a
lower total hCG level of 87 IU/L. A subtraction of the two values
(206 IU/L− 87 IU/L), representing the amount of total hCG molecules
missing the CTP, gave a raised value of 119 IU/L. The Johnson and
Johnson non-CTP based hCG assay, which detects hCG free ß-subunit
levels, returned a level of 175 IU/L, equivalent to 85% of the total hCG
(206 IU/L). The predominance of free ß-subunit is a hallmark for the fa-
milial hCG syndrome. (Cole, 2012).
We were then able to obtain heparin plasma samples from her four
children and tested them with the Abbott Architect and Roche Cobas
total hCG assays (Table 1). All four children had raised total hCG levels.
The free ß-subunit predominance, the raised total of hCG molecules
missing the C-terminal peptide, the elevated hCG levels in all her chil-
dren and the absence of hyperglycosylated hCG were in keeping with
the diagnosis of familial hCG syndrome.(Cole, 2012) The patient was
counselled that she did not require a hysterectomy nor further oncolog-
ical treatment.
Discussion
We believe this to be the ﬁrst case of familial hCG syndrome report-
ed in New Zealand. It is important to note that familial hCG syndrome is
rare, with only 10 cases reported in published literature.(Cole, 2012) To
date, The USA hCG Reference Service has observed only 25 cases world-
wide (L. Cole, Personal communication, August 20th 2013).
More common causes of a raised hCG such as pregnancy, gestational
trophoblastic disease, germ cell malignancies and drug doping must be
excluded before considering a diagnosis of familial hCG syndrome.
However, it is important to consider this diagnosis, in order to prevent
unnecessary oncological treatment in the setting of presumed gesta-
tional trophoblastic neoplasia or germ cell tumourswithout radiological
or histological evidence of malignancy, as well as to avoid social stigma
in the setting of presumed drug doping in sports. In particular, systemic
chemotherapy causes acute toxicity and is associated with long-term
sequelae including secondary malignancies, fertility issues and in-
creased risk for metabolic syndrome. Of the ten cases reported, four pa-
tients received methotrexate, two patients received other systemic
chemotherapy and one patient underwent a total hysterectomy before
a diagnosis of familial hCG syndrome was made. (Cole, 2012) Children
of affected families would also be spared unnecessary investigations in
the setting of persistently raised but low levels of total HCG following
a pregnancy or on incidental ﬁnding.The differential diagnosis for this patient on presentation to Medical
Oncology included GTN, PSTT or occult malignancy. PSTT, a rare variant
of gestational trophoblastic disease, may present with a persistent mild
elevation in hCG, often lower than that seen in typical gestational tro-
phoblastic neoplasia. It can have a latent onset after gestation but has
the potential for distant metastases which are usually not responsive
to systemic chemotherapy at advanced stages (Shih and Kurman,
2001; Kim, 2003). If PSTT is conﬁned to the uterus, standard treatment
is with total hysterectomywith a curative intent. Although uncommon,
malignancies other than germ cell tumours can also present with
elevated hCG levels such as with upper gastrointestinal, lung and
breast cancer. (Kenny and McAleer, 2004; Szturmowicz et al., 1995;
Reisenbichler et al., 2009).
The USA hCG Reference Service and their different hCG assays
played a key role in the discovery of her high proportion of hCG mole-
cules either missing the CTP or having a mutated form of CTP. Although
the free ß-subunit predominance is a hallmark of the familial hCG syn-
drome, this can also be present in PSTT and does not exclude PSTT as a
differential. However, the hyperglycosylated hCG level, usually raised
in active gestational trophoblastic disease, (Cole et al., 2006) was low
in our index case, reﬂecting the absence or reduced number of invasive
cytotrophoblast cells.
The testing and conﬁrmatory results of raised total hCG in all four
children then led to our diagnosis of familial hCG syndrome. The inher-
itance pattern for familial hCG syndrome is suggestive of a dominant
gene with high penetrance; all four children of our index patient were
affected. The syndrome did not impact upon this patient's fertility, con-
sistent with published literature. (Cole, 2012) There is active research
into the speciﬁc gene mutations which drive the production of the mu-
tated hCG molecules internationally (Ulf-Hakan and Henrik, 2013) and
further serum andurine sampleswill be obtained from our patient's im-
mediate and extended family to contribute to this work.
In summary, amultidisciplinary approach and additional hCG assays
conducted by the USA hCG reference servicewere pivotal inmaking the
diagnosis of this rare syndrome, without which our patient may have
had unnecessary oncological treatment.
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